# Title
The O
3-hydroxy-3-methylglutaryl B-Gene
coenzyme I-Gene
A I-Gene
reductase I-Gene
inhibitor O
fluvastatin: B-Chemical
effect O
on O
human B-Species
cytochrome B-Gene
P-450 I-Gene
and O
implications O
for O
metabolic O
drug O
interactions. O

# Abstract
Fluvastatin, B-Chemical
a O
3-hydroxy-3-methylglutaryl B-Gene
coenzyme I-Gene
A I-Gene
reductase I-Gene
inhibitor, O
was O
metabolized O
by O
human B-Species
liver O
microsomes O
to O
5-hydroxy-, B-Chemical
6-hydroxy-, B-Chemical
and I-Chemical
N-deisopropyl-fluvastatin. I-Chemical
Total O
metabolite O
formation O
was O
biphasic O
with O
apparent O
Km O
values O
of O
0.2 O
to O
0.7 O
and O
7.9 O
to O
50 O
microM O
and O
intrinsic O
metabolic O
clearance O
rates O
of O
1.4 O
to O
4 O
and O
0.3 O
to O
1.5 O
ml O
h O
mg O
microsomal O
protein O
for O
the O
high O
and O
low O
Km O
components, O
respectively. O
Several O
enzymes, O
but O
mainly O
CYP2C9, B-Gene
catalyzed O
fluvastatin B-Chemical
metabolism. O
Only O
CYP2C9 B-Gene
inhibitors O
such O
as O
sulfaphenazole B-Chemical
inhibited O
the O
formation O
of O
both O
6-hydroxy- B-Chemical
and I-Chemical
N-deisopropyl-fluvastatin. I-Chemical
5-Hydroxy-fluvastatin B-Chemical
formation O
was O
reduced O
by O
compounds O
that O
are O
inhibitors O
of O
CYP2C9, B-Gene
CYP3A, B-Gene
or O
CYP2C8. B-Gene
Fluvastatin B-Chemical
in O
turn O
inhibited O
CYP2C9-catalyzed O
tolbutamide B-Chemical
and O
diclofenac B-Chemical
hydroxylation O
with O
Ki O
values O
of O
0.3 O
and O
0.5 O
microM, O
respectively. O
For O
CYP2C8-catalyzed O
6alpha-hydroxy-paclitaxel B-Chemical
formation O
the O
IC50 O
was O
20 O
microM O
and O
for O
CYP1A2, B-Gene
CYP2C19, B-Gene
and O
CYP3A B-Gene
catalyzed O
reactions, O
no O
IC50 O
could O
be O
determined O
up O
to O
100 O
microM O
fluvastatin. B-Chemical
All O
three O
fluvastatin B-Chemical
metabolites O
were O
also O
formed O
by O
recombinant O
CYP2C9, B-Gene
whereas O
CYP1A1, B-Gene
CYP2C8, B-Gene
CYP2D6, B-Gene
and O
CYP3A4 B-Gene
produced O
only O
5-hydroxy-fluvastatin. B-Chemical
Km O
values O
were O
approximately O
1, O
2.8, O
and O
7.1 O
microM O
for O
CYP2C9, B-Gene
CYP2C8, B-Gene
and O
CYP3A, B-Gene
respectively. O
No O
difference O
in O
fluvastatin B-Chemical
metabolism O
was O
found O
between O
the O
CYP2C9R144 O
and O
CYP2C9C144 O
alleles, O
suggesting O
the O
absence O
of O
polymorphic O
fluvastatin B-Chemical
metabolism O
by O
these O
alleles. O
CYP1A2, B-Gene
CYP2A6, B-Gene
CYP2B6, B-Gene
CYP2C19, B-Gene
CYP2E1, B-Gene
and O
CYP3A5 B-Gene
did O
not O
produce O
detectable O
amounts O
of O
any O
metabolite. O
This O
data O
indicates O
that O
several O
human B-Species
cytochrome B-Gene
P-450 I-Gene
enzymes O
metabolize O
fluvastatin B-Chemical
with O
CYP2C9 B-Gene
contributing O
50-80%. O
Any O
coadministered O
drug O
would O
therefore O
only O
partially O
reduce O
the O
metabolic O
clearance O
of O
fluvastatin; B-Chemical
therefore, O
the O
likelihood O
for O
serious O
metabolic O
drug O
interactions O
is O
expected O
to O
be O
minimal. O